New release date for Sedana Medical’s year-end report 2018

Report this content

Sedana Medical AB (publ) announce today that the year-end report for 2018 will be released Tuesday 12th of March 2019 at 07.00 CET instead of 21st of March. 

Sedana Medical invites all interested parties to a webcast conference call, with presentation of the year-end report at. 10.30 CET. Sedana Medical's CEO Christer Ahlberg and CMO Peter Sackey participate in the presentation held in English.

Information on how to participate:

The webcast including the presentation material, which can also be seen afterwards, is reached at:

Questions can be made in writing via the webcast or verbally via the telephone conference.

To participate in the conference call, please dial one of the following numbers:

FI: +358981710520
FR: +33170750721
DE: +4969222220380
SE: +46850558351
NL: +31207219495
UK: +443333009272
US: +18338230590

The presentation material will also be available on the Sedana Medical website at under Investors / Presentations. From there it will also be possible to reach the webcast and see the recorded version of the webcast and the conference call afterwards.

For additional information, please contact:

Christer Ahlberg, VD, Sedana Medical AB
+46 70 675 33 30

Maria Engström, CFO, Sedana Medical AB
+46 70 674 33 30

Thomas Eklund, styrelseordförande, Sedana Medical AB
+46 70 824 20 25

Sedana Medical is listed on Nasdaq First North in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00,


Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanically ventilated patients. A major clinical registration study is currently ongoing to obtain market approval in Europe for inhalation sedation in intensive care units with the pharmaceutical IsoConDa® (isoflurane).

Sedana Medical has direct sales in the Nordic countries, Germany, France, Great Britain and Spain as well as external distributors in the rest of Europe, Canada, Australia, Japan and South Korea. The company headquarters are based in Stockholm, Sweden with R&D operations in Ireland. 



Documents & Links